News >

FDA Panel Backs Blinatumomab for MRD+ ALL

Jason Harris
Published: Wednesday, Mar 07, 2018

David M. Reese, MD

David M. Reese, MD
Blinatumomab (Blincyto) received an 8 to 4 vote from the FDA’s Oncologic Drugs Advisory Committee (ODAC) in favor of an indication for the treatment of minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x